The 8th International Conference on the Tear Film & Ocular Surface: Basic Science and Clinical Relevance will occur from September 7-10, 2016 in Montpellier, France.
This Conference is sponsored by TFOS (www.TearFilm.org) and is designed to assess the current knowledge and ‘state of the art’ research on the structure and function of the tear film and ocular surface in health and disease. The TFOS Conference will also promote an international exchange of information that will be of value to basic scientists involved in eye research, to clinicians in the eye care community, and to companies with an interest in the diagnosis and/or treatment of tear film and ocular surface disorders.
”TFOS has organized some of the leading conferences on diseases associated with the surface of the eye, with special focus on Dry Eye Disease (DED). In 2007, TFOS convened the leading conference, Dry Eye Workshop (DEWS) and will now convene leading academic researchers, clinicians and pharmaceutical companies to further the knowledge of DED in the sequel DEWSII. This conference gives Redwood Pharma a good opportunity to remain current on state-of-the-art R&D and to engage potential industrial partners regarding the development of Redwood Pharma’s dry eye candidate drug, RP101. The Company will attend the DEWSII workshop and will be open for partnering meetings,” says CEO Martin Vidaeus.
For more information:
Martin Vidaeus, CEO Redwood Pharma AB (publ.)
Tel: +46 (0) 70 232 29 29
E-mail: martin.vidaeus@redwoodpharma.se
About Redwood Pharma
Redwood Pharma develops ophthalmic products for unmet medical needs. The Company’s first project is the development of drug candidate RP101 with a known active substance against chronic dry eye in postmenopausal women who have moderate to severe symptoms. With the drug delivery platform IntelliGel® the release of active substances is controlled. Through the use of IntelliGel®, Redwood Pharma can also improve dosing of other established drugs. Redwood Pharma’s strength lies in formulation and early clinical development. Revenues will be generated through licensing agreements with pharmaceutical companies that have capabilities to manufacture and sell commercial products worldwide.
Redwood Pharma AB (publ.) is listed on AktieTorget, a Swedish Multilateral Trading Facility (Ticker: REDW.ST, ISIN: SE008294789).
For more information visit: www.redwoodpharma.com